# ADMA Biologics Inc (ADMA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $9.62, market value $2.2 billion.

## Valuation
- **P/E (trailing): 13.7×** (5-yr avg 25.8×, 3-yr avg 25.8×). ADMA Biologics Inc trades at 13.7× trailing earnings, well below its own five-year average of 25.8×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 9.8×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 4.2×**. Each dollar of revenue is priced at 4.2×.
- **Price / book: 5.3×**. The shares trade at 5.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 9.2×**. Enterprise value is 9.2× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 5.4%** (5-yr avg -14.0%). Free cash flow equals 5.4% of the market value, above its five-year average of -14.0%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 7.3%**. The inverse of the P/E: 7.3% of the price is earned each year.

## Profitability
- **Gross margin: 64.7%**. ADMA Biologics Inc keeps 64.7% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 43.8%**. 43.8% of revenue is left after running the business, an exceptional level.
- **Net margin: 28.8%**. 28.8% of each dollar of sales reaches the bottom line.
- **Return on equity: 30.8%**. 30.8% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 38.4%**. Return on all capital, debt included, is 38.4%: comfortably above what that capital costs.
- **Return on assets: 27.1%**. Each dollar of assets produces 27.1% of profit.

## Growth
- **Revenue growth (1 yr): 19.6%** (3-yr 49.0%/yr, 5-yr 64.6%/yr). Revenue grew 19.6% over the last year, against 64.6% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -25.9%**. Earnings per share fell 25.9%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.15**. Debt is 0.15 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. ADMA Biologics Inc holds more cash than debt.
- **Altman Z-score: 11.70**. A Z-score of 11.70 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. ADMA Biologics Inc does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -43.1%** (YTD -47.3%, 3-mo 20.7%). The shares are down 43.1% over twelve months including dividends.
- **From 52-week high: -53.0%** (33.4% above the low). Trading 53% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 55**. An RSI of 55 is neutral.
- **Beta (1 yr): 0.88** (volatility 54%). Beta of 0.88 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ADMA · Page: https://foliofundamentals.com/stocks/adma

Not investment advice.